NT5E and glioblastoma: In the 194 tumor cohort, CD73 expression was slightly lower in recurrent/residual tumors as compared to primary lesions (Fig. 5D; Supplementary Data 9) and in IDH-WT glioblastoma with an unmethylated (unsilenced) MGMT promoter compared to ones with MGMT promoter methylation (Fig. S7h and Supplementary Data 10).